Document is current
Any future updates will be listed below
-
Authors
Reardon, Brendan
Moore, Nathanael D.
Moore, Nicholas S.
Kofman, Eric
AlDubayan, Saud H.
Cheung, Alexander T. M.
Conway, Jake
Elmarakeby, Haitham https://orcid.org/0000-0002-4315-4347
Imamovic, Alma
Kamran, Sophia C. https://orcid.org/0000-0001-9283-6515
Keenan, Tanya
Keliher, Daniel
Konieczkowski, David J.
Liu, David
Mouw, Kent W.
Park, Jihye
Vokes, Natalie I. https://orcid.org/0000-0002-3766-5335
Dietlein, Felix
Van Allen, Eliezer M. https://orcid.org/0000-0002-0201-4444
- License Information
-
More Information
Article History
Received: 24 September 2020
Accepted: 14 July 2021
First Online: 30 September 2021
Competing interests
: E.M.V.A. holds consulting roles with Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio, and Monte Rosa. E.M.V.A. has received research support from Novartis and BMS. E.M.V.A. owns equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft, and Monte Rosa and has received travel reimbursement from Roche–Genentech. E.M.V.A., B.R., and N.D.M. have institutional patents filed on methods for clinical interpretation (international application number PCT/US2019/027338). N.I.V. has served on the advisory board to Sanofi. The remaining authors declare no competing interests.
